cerrar
Tagged with Pricing

Cracking the Elusive GtN Code in Pharma Pricing
Merck’s Kaushal Kishore attempts to illustrate why pharma companies have struggled to crack what he calls "the Gross to Net (GtN) code." He outlines…

Pharma Braces for Widespread Impact of US IRA
The US Inflation Reduction Act (IRA) passed last year by the Biden administration and hotly contested by the innovative pharma industry, has started…

First Ten Drugs Subject to Medicare Pricing Negotiations
The subject of intense industry criticism from the likes of lobby groups, Big Pharma, and biotech alike, the Inflation Reduction Act (IRA) subjects…

German Stakeholders Ramp up Critique of Proposed Healthcare…
Following the COVID-19 pandemic and the resulting supply chain disruptions, global drug pricing and access reforms have multiplied. The Inflation…

Betting the Bottom Dollar on AI in Pricing & Market Access
Merck KGaA's Marco Rauland and Kaushal Kishore examine how artificial intelligence and machine learning can best be applied in pharmaceutical pricing…

Four Insights from Amgen CEO Bob Bradway
Founded in 1980 “at the dawn of a biotechnology revolution,” Amgen has held its ground throughout its more than 40-year history with innovative…

Merck’s IRA Lawsuit Comes Under Fire from Own Shareholders
Big Pharma has been raging against the US’s Inflation Reduction Act (IRA) ever since it was passed last year. Merck (MSD global) has recently taken…

Inside Belgium’s Drug Reimbursement Reform
Belgium’s drug reimbursement system has become increasingly lengthy and complex, compromising patient access to innovative medicines. The roadmap…

US Insulin Pricing: 5 Key Facts to Know
After considerable government pressure to reduce insulin costs in the US, Eli Lilly recently slashed its prices by as much as 70 percent, followed by…

Price Controls & Reference Pricing Systems: Switzerland
An extract from PharmaBoardroom’s new country-focused series on market access and health technology assessment (HTA), this piece gives the lowdown…

UK Pharma Industry Warns of Declining Competitiveness
The UK government has decided to go ahead with a much-debated increase in the revenue clawback rate —from 24.4 percent to 27.5 percent— for…

Improving the EBITDA of a $4.3 Trillion Investment in Healthcare
Blue Spoon Consulting's John G. Singer takes aim at the recent anti-Big Pharma rhetoric around the drug pricing crisis in the US, instead calling for…
We use cookies to ensure that we give you the best experience on our site. For more info

See our Cookie Privacy Policy Here